Stocks
Alnylam Pharmaceuticals (ALNY) EV/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EV/EBITDA | ? | -12.1 | -17.6 | -26.3 | -31.4 | -105.9 | -132.1 | ||
| Changes by years, y/y, % | +61% | +46% | +49% | +19% | +238% | +69.7% | |||
Alnylam Pharmaceuticals. EV/EBITDA
Alnylam Pharmaceuticals. EV/EBITDA, changes, %
Alnylam Pharmaceuticals (ALNY) EV/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EV/EBITDA | ? | -55.0 | -78.6 | -98.1 | 274.7 | -232.0 | -132.1 | |
| Changes by years, y/y, % | +75% | +100% | +194% | -1 057% | +322% | |||
| Changes by quarters, q/q, % | +92% | +43% | +25% | -380% | -184% | |||
